FDA Clears New Blood Test that Could Speed Alzheimer’s Diagnosis and Treatment

Translate to Spanish or other 102 languages!

With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed. Image for illustration purposes
With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed. Image for illustration purposes
- Advertisement -

By George Washington University

Newswise – With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed.

This week, the FDA cleared Roche’s Elecsys pTau181 test — only the second blood-based biomarker test approved this year for Alzheimer’s disease. The test, developed with Eli Lilly, gives primary care physicians a faster way to help rule out Alzheimer’s in patients showing signs of cognitive decline, potentially reducing reliance on costly PET scans and getting patients to answers — and treatment — sooner.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS to Host Annual Think Pink Parade to Drive Breast Cancer Awareness, Oct. 3rd

Breast cancer remains one of the most commonly diagnosed cancers among women in the United States and is a leading cause of cancer-related deaths.

DHR Health Enhances Ear, Nose, and Throat Care with Addition of Dr. Tess Hill

As part of its ongoing commitment to expanding access to outstanding healthcare throughout the Rio Grande Valley, DHR Health is pleased to welcome Dr. Tess Hill to its growing team of physicians. Dr. Hill joins DHR Health as an otolaryngologist (ear, nose and throat physician) and looks forward to providing compassionate, patient-centered care.

Accelerator Program Relaunches Oct. 15 with Expanded Focus on AI and Healthcare

AltaCair Foundation, in partnership with Genentech as the 2026 co-host, will host its fourth annual Accelerator summit on Thursday, October 15, 2026, from 8:00 a.m. to 12:00 p.m. at the Harlingen Convention Center.

Scientists Discover Key Biological Link Between Endometriosis and Chronic Pain

New Yale research may help explain why some patients with a small number of growths experience debilitating pain, while others with more widespread disease do not have symptoms.
- Advertisement -